CSL CSL is a global biopharma company working to create enduring impact for patients and public health. OUR GLOBAL MANUFACTURING AND OFFICE PRESENCE OUR BUSINESS US$15.6b in annual revenue 100+ countries that CSL provides lifesaving products to patients US$2.92 dividend per share for 2025 CSL uses its deep expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as haemophilia, immune deficiencies, influenza and iron deficiency anaemia. CSL innovates at every step of the process. It pioneers therapies and vaccines, improves patients’ and donors’ experiences, broadens access to treatments, and tackles complexity at scale through specialised manufacturing processes. Helping address unmet medical needs is what sets CSL apart. CSL’s focus on diseases where it has a fundamental advantage in understanding the disease and the science; and medicines with a high degree of specialist expertise or manufacturing differentiation. 29,000+ employees globally United States Puerto Rico 2
RkJQdWJsaXNoZXIy MjE2NDg3